Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Paraproteinemias

ClinicalTrials.gov lists 4,255 trials for Paraproteinemias or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 184.

MeSH D010265 Hemic and Lymphatic Diseases C15 C20
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 975 Phase 1/2 Phase 1/2 510 Phase 2 Phase 2 1,333 Phase 2/3 Phase 2/3 33 Phase 3 Phase 3 377 Phase 4 Phase 4 60 Not applicable Not applicable 372 Observational Observational 560 Phase 1 Phase 1 975 Phase 1/2 Phase 1/2 510 Phase 2 Phase 2 1,333 Phase 2/3 Phase 2/3 33 Phase 3 Phase 3 377 Phase 4 Phase 4 60 Not applicable Not applicable 372 Observational Observational 560

Trials per phase (log scale)

2 more sections with rows

66 of the 4,255 trials are tagged with Paraproteinemias itself; the rest are tagged with a narrower condition beneath it.

Get the Paraproteinemias report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Paraproteinemias trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 11 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 221

1990: 2 trials (Phase 2 2) 1991: 1 trials (Phase 2 1) 1992: 4 trials (Phase 2 2, Phase 1/2 1, Phase 1 1) 1993: 6 trials (Observational 2, Phase 3 1, Phase 2 3) 1994: 6 trials (Phase 3 3, Phase 2 3) 1995: 10 trials (Phase 3 4, Phase 2 4, Phase 1/2 1, Phase 1 1) 1996: 15 trials (Observational 1, Phase 3 4, Phase 2 8, Phase 1 2) 1997: 28 trials (Not applicable 3, Phase 3 5, Phase 2 13, Phase 1/2 2, Phase 1 5) 1998: 53 trials (Not applicable 2, Phase 4 1, Phase 3 6, Phase 2/3 1, Phase 2 32, Phase 1/2 2, Phase 1 9) 1999: 53 trials (Not applicable 4, Phase 3 8, Phase 2 25, Phase 1/2 5, Phase 1 11) 2000: 60 trials (Observational 2, Not applicable 5, Phase 3 15, Phase 2/3 1, Phase 2 23, Phase 1/2 9, Phase 1 5) 2001: 56 trials (Observational 4, Not applicable 7, Phase 4 1, Phase 3 5, Phase 2/3 2, Phase 2 22, Phase 1/2 6, Phase 1 9) 2002: 70 trials (Observational 5, Not applicable 5, Phase 3 10, Phase 2/3 1, Phase 2 30, Phase 1/2 8, Phase 1 11) 2003: 74 trials (Observational 3, Not applicable 8, Phase 4 1, Phase 3 16, Phase 2/3 1, Phase 2 18, Phase 1/2 10, Phase 1 17) 2004: 100 trials (Observational 5, Not applicable 7, Phase 4 3, Phase 3 8, Phase 2/3 2, Phase 2 44, Phase 1/2 13, Phase 1 18) 2005: 116 trials (Observational 7, Not applicable 8, Phase 3 12, Phase 2 49, Phase 1/2 16, Phase 1 24) 2006: 127 trials (Observational 14, Not applicable 6, Phase 4 2, Phase 3 19, Phase 2 48, Phase 1/2 16, Phase 1 22) 2007: 129 trials (Other 1, Observational 8, Not applicable 7, Phase 4 2, Phase 3 12, Phase 2/3 1, Phase 2 51, Phase 1/2 16, Phase 1 31) 2008: 161 trials (Observational 20, Not applicable 6, Phase 3 16, Phase 2/3 1, Phase 2 56, Phase 1/2 17, Phase 1 45) 2009: 132 trials (Other 2, Observational 18, Not applicable 6, Phase 3 16, Phase 2/3 4, Phase 2 42, Phase 1/2 19, Phase 1 25) 2010: 157 trials (Observational 20, Not applicable 10, Phase 4 3, Phase 3 13, Phase 2 57, Phase 1/2 26, Phase 1 28) 2011: 134 trials (Observational 15, Not applicable 10, Phase 4 1, Phase 3 14, Phase 2 45, Phase 1/2 22, Phase 1 27) 2012: 148 trials (Observational 13, Not applicable 7, Phase 4 1, Phase 3 7, Phase 2 61, Phase 1/2 21, Phase 1 38) 2013: 132 trials (Observational 17, Not applicable 10, Phase 4 1, Phase 3 12, Phase 2/3 1, Phase 2 40, Phase 1/2 22, Phase 1 29) 2014: 152 trials (Observational 15, Not applicable 9, Phase 4 2, Phase 3 10, Phase 2/3 1, Phase 2 46, Phase 1/2 20, Phase 1 49) 2015: 151 trials (Observational 21, Not applicable 7, Phase 4 2, Phase 3 14, Phase 2/3 1, Phase 2 57, Phase 1/2 14, Phase 1 35) 2016: 159 trials (Observational 25, Not applicable 12, Phase 4 4, Phase 3 9, Phase 2/3 1, Phase 2 59, Phase 1/2 18, Phase 1 31) 2017: 174 trials (Observational 25, Not applicable 6, Phase 4 1, Phase 3 15, Phase 2/3 1, Phase 2 54, Phase 1/2 26, Phase 1 46) 2018: 161 trials (Observational 24, Not applicable 11, Phase 4 2, Phase 3 7, Phase 2/3 1, Phase 2 60, Phase 1/2 17, Phase 1 39) 2019: 190 trials (Observational 29, Not applicable 11, Phase 4 6, Phase 3 14, Phase 2/3 1, Phase 2 50, Phase 1/2 29, Phase 1 50) 2020: 171 trials (Observational 34, Not applicable 25, Phase 4 3, Phase 3 13, Phase 2/3 2, Phase 2 34, Phase 1/2 11, Phase 1 49) 2021: 221 trials (Observational 33, Not applicable 21, Phase 4 1, Phase 3 11, Phase 2 65, Phase 1/2 25, Phase 1 65) 2022: 212 trials (Observational 44, Not applicable 28, Phase 4 6, Phase 3 13, Phase 2 45, Phase 1/2 23, Phase 1 53) 2023: 213 trials (Observational 44, Not applicable 33, Phase 4 2, Phase 3 13, Phase 2/3 2, Phase 2 44, Phase 1/2 31, Phase 1 44) 2024: 201 trials (Observational 44, Not applicable 26, Phase 4 3, Phase 3 16, Phase 2 38, Phase 1/2 21, Phase 1 53) 2025: 195 trials (Observational 32, Not applicable 38, Phase 4 5, Phase 3 11, Phase 2/3 2, Phase 2 50, Phase 1/2 17, Phase 1 40)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 216
2025 195
2024 201
2023 213
2022 212
2021 221
2020 171
2019 190
2018 161
2017 174

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 240 trials starting in 2026 and about 220 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 539 trials still running at the 2026-10-09 snapshot; registered median of 40 months across 2,628 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Paraproteinemias trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 975
Phase 1/2 510
Phase 2 1,333
Phase 2/3 33
Phase 3 377
Phase 4 60
Not applicable 372
Observational 560
Expanded access 34
Unknown 1

How many Paraproteinemias trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 164
Recruiting 599
Enrolling by invitation 16
Active, not recruiting 346
Available 6

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Paraproteinemias trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 184
Celgene 93
Janssen Research & Development, LLC 67
GlaxoSmithKline 46
Amgen 42

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Paraproteinemias? (6)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 342
Melphalan 238
POMALIDOMIDE 190
RITUXIMAB 113
THALIDOMIDE 106

Showing 5 of 6 drugs.

Start your 14-day trial Email me all 6 drugs as a PDF

Interventions as named in the registry (9)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Dexamethasone/Dexamethasone acetate 764
Bortezomib SC 428
X: Lenalidomide 409
SQ Fludarabine 214
Daratumumab SC 212

Showing 5 of 9 interventions.

Start your 14-day trial Email me all 9 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Paraproteinemias trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 4,678 322
Pyrexia 1,609 221
Thrombocytopenia 1,344 181
Febrile neutropenia 1,277 239
Sepsis 1,271 308

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Paraproteinemias? (74)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Implications of monoclonal gammopathy and isoelectric focusing pattern 5 on the free light chain kappa diagnostics in cerebrospinal fluid. Clinical chemistry and laboratory medicine 2025 Yes
Serum free light chains in a racially diverse population including African Americans and populations from South Africa. Blood 2025 Yes
Monoclonal-related neuropathies: diagnosis, prognosis, and outcomes. Hematology. American Society of Hematology. Education Program 2025 Yes
Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial. Annals of internal medicine 2024 Yes
Clinical characteristics and outcome of 318 families with familial monoclonal gammopathy: A multicenter Intergroupe Francophone du Myélome study. American journal of hematology 2023 Yes

Showing 5 of 74 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (7)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages